Literature DB >> 17567125

Marked differences in light-switch behavior of Ru(II) complexes possessing a tridentate DNA intercalating ligand.

Yao Liu1, Richard Hammitt, Daniel A Lutterman, Randolph P Thummel, Claudia Turro.   

Abstract

The tridentate ligand 3-(pyrid-2'-yl)dipyrido[3,2-a:2',3'-c]phenazine (pydppz) has been prepared in two steps by elaboration of 2-(pyrid-2'-yl)-1,10-phenanthroline. Both homoleptic [Ru(pydppz)(2)](2+) and heteroleptic [Ru(tpy)(pydppz)](2+) (tpy = 2,2';6',2' '-terpyridine) complexes have been prepared and characterized by (1)H NMR. The absorption and emission spectra are consistent with low-lying MLCT excited states, which are typical of Ru(II) complexes. Femtosecond transient absorption measurements show that that the (3)MLCT excited state of the heteroleptic complex [Ru(tpy)(pydppz)](2+) (tau approximately 5 ns) is longer-lived than that of the homoleptic complex [Ru(pydppz)(2)](2+) (tau = 2.4 ns) and that these lifetimes are significantly longer than that of the (3)MLCT state of the parent complex [Ru(tpy)(2)](2+) (tau = 120 ps). These differences are explained by the lower-energy (3)MLCT excited state present in [Ru(tpy)(pydppz)](2+) and [Ru(pydppz)(2)](2+) compared to [Ru(tpy)(2)](2+), resulting in less deactivation of the former through the ligand-field state(s). DFT and TDDFT calculations are consistent with this explanation. [Ru(tpy)(pydppz)](2+) and [Ru(pydppz)(2)](2+) bind to DNA through the intercalation of the pydppz ligand; however, only the heteroleptic complex exhibits luminescence enhancement in the presence of DNA. The difference in the photophysical behavior of the complexes is explained by the inability of [Ru(pydppz)(2)](2+) to intercalate both pydppz ligands, such that one pydppz always remains exposed to the solvent. DNA photocleavage is observed for [Ru(tpy)(pydppz)](2+) in air, but not for [Ru(pydppz)(2)](2+). The DNA damage likely proceeds through the production of small amounts of (1)O(2) by the longer-lived complex. Although both complexes possess the intercalating pydppz ligand, they exhibit different photophysical properties in the presence of DNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567125     DOI: 10.1021/ic700484j

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  6 in total

1.  Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy.

Authors:  Jessica D Knoll; Claudia Turro
Journal:  Coord Chem Rev       Date:  2015-01-01       Impact factor: 22.315

2.  New Ru(II) complexes for dual photoreactivity: ligand exchange and (1)O2 generation.

Authors:  Jessica D Knoll; Bryan A Albani; Claudia Turro
Journal:  Acc Chem Res       Date:  2015-07-17       Impact factor: 22.384

3.  UV-vis absorption spectrum of a novel Ru(II) complex intercalated in DNA: [Ru(2,2'-bipy)(dppz)(2,2'-ArPy)]⁺.

Authors:  Agisilaos Chantzis; Thibaut Very; Stéphane Despax; Jean-Thomas Issenhuth; Alex Boeglin; Pascal Hébraud; Michel Pfeffer; Antonio Monari; Xavier Assfeld
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

4.  Ru(ii) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles.

Authors:  Ao Li; Claudia Turro; Jeremy J Kodanko
Journal:  Chem Commun (Camb)       Date:  2018-02-01       Impact factor: 6.222

5.  Excited state investigation of a new Ru(II) complex for dual reactivity with low energy light.

Authors:  J D Knoll; B A Albani; C Turro
Journal:  Chem Commun (Camb)       Date:  2015-05-25       Impact factor: 6.222

Review 6.  Ruthenium polypyridine complexes combined with oligonucleotides for bioanalysis: a review.

Authors:  Shuyu Zhang; Yubin Ding; Hui Wei
Journal:  Molecules       Date:  2014-08-11       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.